Nemonoxacin

Drug Profile

Nemonoxacin

Alternative Names: Nemonoxacin malate sodium chloride; Taigexyn; TG-873870

Latest Information Update: 27 Aug 2016

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer TaiGen Biotechnology
  • Class Piperidines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Community-acquired pneumonia; Skin and soft tissue infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia
  • Phase II Diabetic foot ulcer
  • Phase Unknown Skin and soft tissue infections

Most Recent Events

  • 25 Aug 2016 Nemonoxacin sub-licensed to Productos Cientficos for development and commercialisation in Latin America
  • 19 Jul 2016 Zhejiang Medicine plans a phase I pharmacokinetics trial in China (PO, Capsule) (NCT02840812)
  • 13 Jun 2016 Registered for Community-acquired pneumonia in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top